Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.

Tsuruoka S, Kai H, Usui J, Morito N, Saito C, Yoh K, Yamagata K.

Intern Med. 2013;52(3):303-8. Epub 2013 Feb 1.

2.

Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R.

Hypertens Res. 2006 Nov;29(11):849-56.

PMID:
17345784
3.

Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.

Taguchi I, Toyoda S, Takano K, Arikawa T, Kikuchi M, Ogawa M, Abe S, Node K, Inoue T.

Hypertens Res. 2013 Jul;36(7):608-13. doi: 10.1038/hr.2013.3. Epub 2013 Feb 21.

PMID:
23425956
4.

Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.

Sakamoto M, Suzuki H, Hayashi T, Iuchi H, Isaka T, Sakamoto N, Kayama Y, Tojo K, Yoshimura M, Utsunomiya K.

Cardiovasc Diabetol. 2012 Oct 3;11:118. doi: 10.1186/1475-2840-11-118.

5.

Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.

De Luis DA, Conde R, Gonzalez Sagrado M, Aller R, Izaola O, Perez Castrillon JL, Romero E, Castro MJ.

Eur Rev Med Pharmacol Sci. 2010 Sep;14(9):759-63.

PMID:
21061834
6.
7.

Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients.

Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, Meeusen R, van Loon LJ.

Eur J Appl Physiol. 2010 Jun;109(3):397-404. doi: 10.1007/s00421-010-1362-5. Epub 2010 Feb 4.

8.

Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease.

Ni J, Huang HQ, Lü LL, Zheng M, Liu BC.

Chin Med J (Engl). 2012 Mar;125(6):1147-52.

9.

Relationship of blood pressure and obesity with inflammatory cytokines among African Americans.

DeLoach S, Huan Y, Keith SW, Martinez Cantarin MP, Falkner B.

Ther Adv Cardiovasc Dis. 2011 Jun;5(3):149-57. doi: 10.1177/1753944711408757. Epub 2011 May 9.

PMID:
21558084
11.

Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.

de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gómez-Campderá F, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S206-12.

12.

[Effect of irbesartan in proteinuric non-diabetic renal disease].

de Gracia MC, Molina M, Navarro MJ, Garcia Hernández MA.

Nefrologia. 2005;25(5):509-14. Spanish.

15.

Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial.

Qiu H, Fu P, Fan W, Zuo C, Feng P, Shi P, Cao L, Liu F, Zhou L, Chen F, Zhong H, Gou Z, Liang Y, Shi M.

Phytother Res. 2014 Jan;28(1):132-6. doi: 10.1002/ptr.4973. Epub 2013 Mar 21.

PMID:
23519822
16.

Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.

Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.

Clin Exp Nephrol. 2008 Feb;12(1):33-40. doi: 10.1007/s10157-007-0013-6. Epub 2008 Jan 5.

PMID:
18175062
17.
18.

Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.

De Rosa ML, de Cristofaro A, Rossi M, Baiano A, Cardace P, Albanese L, Vigorito C.

J Cardiovasc Pharmacol. 2001 Sep;38(3):482-9.

PMID:
11486253
19.
20.

Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension.

Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J.

J Cardiovasc Pharmacol. 2005 Dec;46(6):735-9.

PMID:
16306795
Items per page

Supplemental Content

Write to the Help Desk